{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:39:37Z","timestamp":1747179577371,"version":"3.40.5"},"reference-count":65,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2022,4,3]]},"DOI":"10.1080\/17425255.2022.2081148","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T22:10:52Z","timestamp":1653084652000},"page":"245-259","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-867X","authenticated-orcid":false,"given":"Emily N.","family":"Drwiega","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicaco, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.","family":"Griffith","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicaco, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry H.","family":"Danziger","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicaco, IL, USA"},{"name":"College of Medicine, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"volume-title":"Antibiotic resistance threats in the United States, 2019","year":"2019","author":"CDC","key":"cit0001"},{"key":"cit0002","unstructured":"Makary M, Das I, Hashim F, et al. The next pandemic is already here \u2013 tools for stopping it are readily available, if only we agree to use them. 2021 Jan 20. Available from: https:\/\/www.medpagetoday.com\/opinion\/marty-makary\/90795"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32063-8"},{"key":"cit0004","unstructured":"Interagency Coordination Group on Antimicrobial Resistance. No time to wait: securing the future from drug-resistant infections. 2019 April."},{"key":"cit0005","unstructured":"Pharmaceutical Research and Manufacturers of America. 2021 Report on Antimicrobial Resistance. Medicines in Development. 2021."},{"key":"cit0006","unstructured":"Fetroja [package insert]. Florham Park, NJ; 2019."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz825"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00152"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.06.014"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24183314"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00012-07"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020929988"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01801-18"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01582-20"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-17"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00286-6"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.007"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1318"},{"key":"cit0021","doi-asserted-by":"crossref","unstructured":"Greenberg EP, Banin E. Control of biofilm infections by signal manipulation. Berlin (Heidelberg): Springer; 2007. p. 141\u2013156.","DOI":"10.1007\/7142_2007_014"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01194-20"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.703"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1633"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1636"},{"issue":"2","key":"cit0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak KM","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00877-21"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab141"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1909"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa355"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00198-20"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1734"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02163-17"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-18"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz828"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1386"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01391-17"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-16"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz123"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab280"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-004-2171-2"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000069734.38738.C8"},{"key":"cit0043","unstructured":"Shionogi. Safety, tolerability, and pharmacokinetics of cefiderocol in hospitalized pediatric patients. NLM identifier: 04215991 (cited 15 Sept 2021). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04215991"},{"key":"cit0044","unstructured":"Shionogi. Safety, tolerability, and pharmacokinetics of single and multiple doses of cefiderocol in hospitalized pediatric patients. NLM identifier: NCT04335539(cited 2021 Sept 15). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04335539"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.841"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab252"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01086-y"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1498"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.014"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2458-9"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-17"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.03.003"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.03.011"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.10.008"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01022-17"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab188"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1410"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060652"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"cit0062","unstructured":"Fetcroja [package insert]. Amsterdam, The Netherlands: 2020."},{"key":"cit0063","unstructured":"Paterson DS. RCT cefiderocol vs BAT for treatment of Gram-negative BSI (GAMECHANGER). NLM identifier: NCT03869437 (cited 2021 Sept 15). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03869437"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.02.002"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab174"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2022.2081148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T08:20:59Z","timestamp":1655367659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2022.2081148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,3]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,3]]}},"alternative-id":["10.1080\/17425255.2022.2081148"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2022.2081148","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"type":"print","value":"1742-5255"},{"type":"electronic","value":"1744-7607"}],"subject":[],"published":{"date-parts":[[2022,4,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}